a massive study a study on the use of the antimalarial medication hydroxychloroquine in coronavirus patients. in May, the study had found that the treatments didn't appear to help patients hospitalized with the novel coronavirus and instead were associated with heart complications and an increased risk of death.
Some of the study's authors launched an independent third party peer review of the data used in the study, but said that Surgisphere wouldn't transfer over the full dataset. "Based on this development, we can no longer vouch for the veracity of the primary data sources," the authors wrote on Thursday.
The retracted analysis claimed to look at the hospital outcomes of 96,032 hospitalized patients, 14,888 of whom got some form of the antimalarial treatments chloroquine and hydroxychloroquine over the course of four months. The patients came from 671 hospitals from six continents, and the study was led by researchers at the Brigham and Women's Hospital in Boston. Though it was not a randomized controlled trial, it was the largest study of its kind in patients with COVID-19, the disease caused by the novel coronavirus.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessInsider - 🏆 729. / 51 Read more »